🟢 80/100

This product is generally safe

  • Vitamin D: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin D: 0.125mg is 1.2× the Tolerable Upper Intake Level (0.1mg)

Label Data

1 Capsule(s) Serving Size
30 Servings
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

125 mcg (625% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.2× (UL: 0.1 mg) 📚 604 studies (Tier A: 16, B: 251)
RDA 0.015mg This product: 0.125mg UL 0.1mg
45 mcg (38% DV)
✅ Within RDA (0.4× RDA of 0.12 mg) 📚 273 studies (Tier A: 9, B: 175)
RDA 0.12mg This product: 0.045mg

Other Ingredients

natural Vegetable Capsules Microcrystalline Cellulose Magnesium Stearate Silicon Dioxide Stearic Acid

Label Claims — Verification

Nutrient
All Other
All Other (100% of products) Structure/Function (84% of products) Nutrient (73% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

⚠️ Warnings & Precautions

Warning: All forms of Vitamin K may interact with blood thinning medications. If you are taking such medicines please consult with your physician before taking this product.

🧪 Formulation Notes

Essential Vitamins

Product Details

DSLD Entry Date 2022-09-22
Product Type Vitamin
Form Capsule
DSLD ID 277577
Data Updated 2026-04-11

Research Evidence

332 Research Sources
59 Avg Quality Score
220 Meta Analysis
56 Systematic Review
30 Rct
16 Clinical Trial
3 Guideline
3 Regulatory Source
1 Narrative Review
1 Other
1 Openfda Safety
A Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
Meta Analysis The Cochrane database of systematic reviews 2014
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2017
A Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2016
A Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome
Meta Analysis The Cochrane database of systematic reviews 2020
A Direct factor Xa inhibitors versus low molecular weight heparins or vitamin K antagonists for prevention of venous thromboembolism in elective primary hip or knee replacement or hip fracture repair
Meta Analysis The Cochrane database of systematic reviews 2025
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2018
A Antiplatelet agents and anticoagulants for hypertension
Systematic Review The Cochrane database of systematic reviews 2022
A Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Meta Analysis The Cochrane database of systematic reviews 2012
A Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation
Meta Analysis The Cochrane database of systematic reviews 2013
A Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Meta Analysis The Cochrane database of systematic reviews 2014
View all evidence for Vitamin K →

Compare Similar Products

View all Vitamin K products →